首页> 美国政府科技报告 >Single-Dose Absorption and Pharmacokinetics of WR 6026. Phase 1
【24h】

Single-Dose Absorption and Pharmacokinetics of WR 6026. Phase 1

机译:WR 6026的单剂量吸收和药代动力学。第1阶段

获取原文

摘要

WR 6026 is a promising agent for the treatment of visceral leishmaniasis based on experiments in both an animal model and an in vitro test system. This human study was performed in order to increase our understanding of the pharmacokinetics, safety, and tolerance of a single oral 60 mg dose of WR 6026 in healthy male volunteers. Following the administration of a single dose of 60 mg of WR 6026, serial blood specimens and urine collections were obtained in order to assess the pharmacokinetics of this compound. The volunteers were monitored for subjective tolerance by daily interview and for objective toxicity with clinical laboratory tests of hematology and chemistry variables, electrocardiograms, urinalysis, and methemoglobin determinations. All of the subjects tolerated WR 6026 very well with no adverse symptoms. No subject had a significant change in hematological parameters, electrocardiograms, methemoglobin, creatine kinase or urinalysis. (kt)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号